Crucell N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 dec 2008 - 14:05
Statutaire naam
Crucell N.V.
Titel
DSM Biologics and Crucell Announce PER.C6® License Agreement with CSL Ltd.
Bericht
Leiden, The Netherlands/Parsippany, USA, 18 December 2008 – DSM Biologics, a business unit of DSM Pharmaceutical Products, and Dutch biopharmaceutical company Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX), today announced that CSL Limited, a global biopharmaceutical company headquartered in Melbourne, Australia, signed a license agreement allowing CSL to develop protein therapeutics for multiple undisclosed disease targets on the PER.C6® platform. Under the terms of the agreement, CSL is responsible for the development of protein and antibody products resulting from this alliance. Financial terms of the agreement were not disclosed.
“CSL's expertise in the area of drug development and its proven track record of marketed products offer a good match for our PER.C6® production technology,” said Ronald Brus, Crucell's Chief Executive Officer. “This alliance is another example of how we can combine our technology with the discoveries brought forth by other biopharmaceutical discovery companies to advance the development of therapeutic products.”
“This alliance signifies yet another achievement to bring to fruition our mission to position the PER.C6® production technology as an industry standard,” adds Karen King, President of DSM Biologics. “We are pleased to be working with a renowned biopharmaceutical company in which CSL's scientists will be applying their expertise to the development of proteins and antibodies on PER.C6®.”
Datum laatste update: 01 september 2024